Related Experiment Video
Updated: May 17, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment
Anna Dastiridou1, Christos Kalogeropoulos, Periklis Brazitikos
1Department of Ophthalmology, University of Thessalia, Larissa, Greece.
Abstract:
Current treatment guidelines for chronic ocular inflammatory disease recommend the use of steroid-sparing agents. The development of conventional immunomodulatory agents has largely changed the visual outcome in these patients. However, disease refractory to these treatment modalities has led to the use of new biologic-response modifiers, agents that target specific components of the pathogenetic process. The purpose of this review is to summarize the mechanism of action, experimental evidence, side effects and current experience with the use of rituximab, daclizumab, abatacept, anakinra and IFN-α in ocular inflammatory disease.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...